Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02514525 · ClinicalTrials.gov registry record · NA

Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System

A NA study of Barrett Esophagus, sponsored by Pentax Medical.

Active
Registry status
NA
Development phase
150
Enrollment target
11
Study locations

NCT02514525 is a NA study of Barrett Esophagus that is active but no longer recruiting, run by Pentax Medical. The registered enrollment target is 150 participants, below the 3,561-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02514525, a NA study of Barrett Esophagus, is active but no longer recruiting, sponsored by Pentax Medical.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
11
Study locations

Study Summary

To evaluate the efficacy and safety of the CryoBalloon Focal Ablation System for the treatment of previously-untreated ("treatment naïve") Barrett's Esophagus (BE)

Conditions Studied

Interventions

  • DEVICE CryoBalloon Ablation System

Study Locations (11)

New York

  • Northwell Health - Manhasset
  • New York Presbyterian Hospital-Columbia University Medical Center - New York

Pennsylvania

  • Geisinger Medical Center - Danville
  • Thomas Jefferson University - Philadelphia

California

  • UC Irvine - Orange

Florida

  • Sarasota Memorial Hospital - Sarasota

Illinois

  • University of Chicago - Chicago

Maryland

  • John Hopkins - Baltimore

Minnesota

  • Mayo Clinic - Rochester

North Carolina

  • University of North Carolina School of Medicine - Chapel Hill

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2016-03
Est. Completion 2025-12
Phase NA

Sponsor

Pentax Medical

4 total trials

What the Registry Record Tells You About NCT02514525

The ClinicalTrials.gov registry entry for NCT02514525 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,561-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (96% lower). The listed sponsor is Pentax Medical, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Barrett Esophagus appearing as the primary indexed condition, and to 1 intervention - of which CryoBalloon Ablation System is the first listed.

NCT02514525 reports 11 study locations spanning 9 distinct geographic areas - top geographies include New York, Pennsylvania, California.

Frequently Asked Questions

What is clinical trial NCT02514525 about?

NCT02514525 is a clinical study titled "Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System". To evaluate the efficacy and safety of the CryoBalloon Focal Ablation System for the treatment of previously-untreated ("treatment naïve") Barrett's Esophagus (BE)

What is the current status of trial NCT02514525?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2016-03. Estimated completion is 2025-12.

What conditions does trial NCT02514525 study?

This clinical trial studies the following conditions: Barrett Esophagus.

What interventions are being tested in trial NCT02514525?

The interventions under investigation include: CryoBalloon Ablation System (DEVICE).

Who is sponsoring clinical trial NCT02514525?

This trial is sponsored by Pentax Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02514525 being conducted?

This trial has 11 study locations across California, Florida, Illinois, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Barrett Esophagus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.